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Abstract: Human respiratory syncytial virus (HRSV) causes substantial morbidity and mortality
in vulnerable patients, such as the very young, the elderly, and immunocompromised individuals
of any age. Nosocomial transmission of HRSV remains a serious challenge in hospital settings,
with intervention strategies largely limited to infection control measures, including isolation of
cases, high standards of hand hygiene, cohort nursing, and use of personal protective equipment.
No vaccines against HRSV are currently available, and treatment options are largely supportive care
and expensive monoclonal antibody or antiviral therapy. The limitations of current animal models
for HRSV infection impede the development of new preventive and therapeutic agents, and the
assessment of their potential for limiting HRSV transmission, in particular in nosocomial settings.
Here, we demonstrate the efficient transmission of HRSV from immunocompromised ferrets to both
immunocompromised and immunocompetent contact ferrets, with pathological findings reproducing
HRSV pathology in humans. The immunocompromised ferret-HRSV model represents a novel tool
for the evaluation of intervention strategies against nosocomial transmission of HRSV.
Keywords: respiratory syncytial virus; animal model; ferret; immunocompromised;
transmission; contact
1. Introduction
Human respiratory syncytial virus (HRSV) is the leading cause of acute lower respiratory tract
infection in children less than 5 years of age, with high hospitalization rates in infants younger
than 6 months [1]. It also causes significant morbidity in adults, and contributes to excess mortality in
older individuals and immunocompromised individuals of any age [2,3]. In the latter, infection may
be prolonged and often complicated by bacterial co-infection, leading to pneumonia and severe
respiratory distress [4]. Outbreaks among vulnerable patients in hospital settings are of particular
concern [5,6]. Nosocomial transmission poses a substantial risk and remains a serious challenge
for hospital infection control. In the absence of an effective vaccine, HRSV treatment options are
largely limited to supportive care and expensive monoclonal antibody or antiviral therapy [7,8].
Infection control measures, including isolation of cases, high standards of hand hygiene, cohort nursing,
and use of personal protective equipment have been reported as relatively effective in the prevention
and control of HRSV outbreaks in nosocomial settings [5,9,10]. The prophylaxis use of monoclonal
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antibody therapy also can reduce nosocomial transmission [11]. There is nonetheless a need for a
larger armamentarium of HRSV-specific treatments and evidence-based control measures for HRSV
infection prevention and control.
The lack of an appropriate animal model fully recapitulating HRSV pathogenesis of infection and
disease has long represented a hurdle for the development of new intervention strategies against HRSV,
including its spread in nosocomial settings [12]. In humans, HRSV is transmitted by direct contact
and large aerosol droplets, and via contaminated surfaces, initiating viral replication in the upper
respiratory tract after an incubation period of 4–5 days [2]. In severe cases, HRSV further spreads to
and replicates in the lower respiratory tract. The virus replicates in ciliated epithelial cells along the
respiratory tract, as well as in type I and type II alveolar pneumocytes, resulting in inflammation and
necrosis. Animal models for HRSV infection are mostly semi-permissive, requiring a large inoculum
of HRSV to result in a productive infection [12]. They include non-human primate (NHP) models,
which, apart from chimpanzees and African green monkeys, generally develop no or little clinical
signs or pathological changes. The most used non-primate models of HRSV infection are cotton rats,
mice, and the neonatal lamb. These models have contributed to improving our understanding of
HRSV pathogenesis and host immune responses [13,14]. Furthermore, NHPs and cotton rats may also
develop atypical enhanced disease following vaccination with formalin-inactivated HRSV, as seen in
humans. However, they all have their limitations [12]. In none of these models HRSV is transmitted to
contact individuals, or they are highly impractical to study transmission.
The ferret model of HRSV infection had initially yielded disappointing results, with poor,
age-dependent replication of the virus in the lower respiratory tract [12,15]. However, we reported
recently that a low-passage clinical isolate of HRSV efficiently replicates in both the upper and lower
respiratory tracts of adult ferrets [16]. In addition, we described the use of immunocompromised ferrets
as a relevant model for HRSV infection in immunocompromised individuals [16]. It is characterized by
high replication levels in the lower respiratory tract, with viral antigen detected in tracheal, bronchial,
and bronchiolar ciliated epithelial cells, and by prolonged viral replication and shedding, reflecting the
increased viral loads and delayed viral clearance observed in immunocompromised individuals.
Prolonged infection is thought to be an important risk factor for nosocomial transmission [17].
Prince et al. reported that infant ferrets generate higher virus loads than adult ferrets, resulting in
successful contact transmission of HRSV from infant ferrets to their mother [15]. Recently, Chan et al.
showed limited horizontal transmission in a preliminary study between immunocompetent ferrets
without proof of replicating virus in the contact ferrets [18]. The immunocompromised ferret-HRSV
model [16] offers a new tool to study HRSV transmission and its prevention, which may be used
to address the potential of intervention strategies, including vaccines and antibody or antiviral
treatments, to block or limit HRSV transmission. Here we report the effective transmission of a
low-passage clinical isolate of HRSV from immunocompromised ferrets to both immunocompetent
and immunocompromised contact ferrets with the detection of replicating virus in both donor and
contact ferrets. Both the intranasal and intratracheal route of infection were explored to determine
which site of virus replication would be responsible for transmission of the virus.
2. Materials and Methods
2.1. Virus
A clinical isolate of HRSV subgroup A strain was isolated in human respiratory epithelium
carcinoma (HEp-2) cells from a nasal lavage of an infant hospitalized at Erasmus Medical Centre,
Rotterdam, The Netherlands, in 2011. The virus was passaged exclusively in HEp-2 cells, cultured as
described previously [16]. The challenge stock used in the animal experiments was passage 3,
and was prepared as described previously [16]. Virus titers were determined by end-point titration on
monolayers of HEp-2 cells and cytopathic effect (CPE) screening six days after infection. Viral titers
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were calculated using the method of Spearman and Karber. The challenge stock tested negative for a
large panel of respiratory human viruses and mycoplasma by RT-PCR.
2.2. Ferrets
Ferrets (Mustela putorius furo) were 16- to 18-month-old purpose-bred males, which were
seronegative for Aleutian disease virus, and RSV subgroup A and B. They were housed in
groups of 2 to 12, as described previously [16]. Male ferrets were selected irrespective of any
HRSV-related parameter, because male ferrets would be more robust to endure the treatment
procedures. The present experiment complied with all national and international guidelines for
care and use of animals and was ethically approved on 15 December 2015 by the Dutch Central
Committee Animal Experiments (CCD), protocol number AVD277002015161.
Immunocompromised ferrets received orally twice daily the immunosuppressive medication
of 20 mg/kg of body weight (bw) Mycophenolate mofetil (MMF) (CellCept®, Roche,
Woerden, The Netherlands), 0.5 mg/kg bw tacrolimus (Prograft®, Astellas Pharma BV, Leiderdorp,
The Netherlands), 8 mg/kg bw prednisolone (Hospital Pharmacy, UMCN St Radboud,
Nijmegen, The Netherlands), together with antibiotic prophylaxis of 10 mg/kg bw amoxicillin
and 2.5 mg/kg bw clavulanic acid (Pharmachemie BV, Haarlem, The Netherlands), as described
previously [16,19].
2.3. HRSV Transmission Experiment
A total of twenty-four ferrets were randomly assigned to the following treatment groups
(Figure 1): (A) 2 immunocompromised donor ferrets infected with HRSV via the intra-tracheal route of
inoculation; (B) 2 immunocompromised donor ferrets infected with HRSV via the intra-nasal route
of inoculation; (C) 5 immunocompromised contact ferrets placed on day 5 post-inoculation (dpi)
with group A ferrets; (D) 5 immunocompetent contact ferrets placed on 5 dpi with group A ferrets;
(E) 5 immunocompromised contact ferrets placed on 5 dpi with group B ferrets; (F) 5 immunocompetent
contact ferrets placed on 5 dpi with group B ferrets.
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Figure 1. Schematics overview of the experimental design; ferret groups are lettered (A–F); red 
ferrets are immunocompromised ferrets; black ferrets are immunocompetent ferrets; contact ferrets 
(group C–F) are placed in the same cages as donor ferrets (group A,B) on day 5 post-inoculation 
(dpi); all ferrets are euthanized at 13 dpi. Days of collection of nose swabs, throat swabs, 
broncho-alveolar lavages (BAL), and respiratory tract samples are indicated with dark squares; 
samples used for viral sequencing are indicated with patterns. 
Figure 1. Sche ati erview of th experimental design; ferret groups are lettered (A–F);
red ferrets are immunocompromised ferrets; black ferrets are i mun compe ent f rrets; contact ferrets
(group C–F) are placed in the same cages as donor ferr ts (group A,B) on day 5 post-inoculation (dpi);
all ferrets re uthaniz d at 13 dpi. Days of collection f n s swabs, throat s s, broncho-alveolar
lavages (BAL), and respiratory tract samples are indicated with dark squares; samples used for viral
sequencing are indicated with patterns.
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After a one-week acclimatization period, the ferrets assigned to group A, B, C, and E (Figure 1)
were started on the immunosuppression protocol, with daily oral prophylactic antibiotics starting
four days before HRSV infection, and twice-daily oral immunosuppressants starting three days before
HRSV infection. The ferrets assigned to group A and B were inoculated on day 0. Donor ferrets
sedated with a mixture of ketamine and medetomidine (IM doses of 0.2 and 0.01 mL/kg body weight,
respectively) were inoculated with 105 median tissue-culture infective dose (TCID50) of low-passage
clinical isolate HRSV subgroup A by intra-tracheal (IT; group A) or intra-nasal (IN; group B) inoculation
with a volume of 3 or 0.3 mL, respectively.
The ferrets assigned to group C to F were introduced in the cages of group A and B ferrets on 5 dpi
to enable direct contact. Throat (Copan; rayon tipped) and nose (Copan; polyester tipped) swabs were
collected from all ferrets daily from 3 dpi onwards in a 3mL virus transport medium [16]. Donor ferrets
were euthanized by exsanguination under anesthesia with ketamine-medetomidine at 13 dpi and
contact ferrets at day 8 post-exposure (dpe; corresponding to 13 dpi). Broncho-alveolar lavages (BAL)
and samples of the nasal turbinates, trachea, primary bronchus, and lung parenchyma were collected
upon autopsy.
All personnel involved in the collection of study data on a day-to-day basis and all personnel
performing the laboratory analysis in which interpretation of the data is required were not aware of the
so-called Random Treatment Allocation Key at any time prior to completion of the study. All samples
were labeled with a unique sample number.
2.4. Samples and Assays
All samples were processed within four hours of sample collection. Infectious virus titers and
concentrations of viral RNA were measured by virus isolation and reverse transcription-PCR (RT-PCR),
respectively, as previously described [16]. Samples of the nasal turbinates, trachea, primary bronchus,
and right lung were weighed and subsequently homogenized with a FastPrep-24 (MP Biomedicals,
Eindhoven, The Netherlands) in medium and centrifuged briefly before viral load assessment by virus
isolation and quantitative RT-PCR.
RNA extraction was performed using a MagNA Pure 96 (Roche Diagnostics Nederland B.V.,
Almere, The Netherlands) and MagNA Pure 96 DNA and Viral NA Small Volume Kit with an
input volume of 190 µL and output volume of 100 µL according to the manufacturer’s instructions
(Roche Diagnostics Nederland B.V.). The extraction was internally controlled by the addition of a
known concentration of phocine distemper virus (PDV) [20]. 20 µL extracted RNA was amplified in
a 50 µL final volume, containing 12.5 µL 4× TaqMan Fast Virus 1-Step Master Mix (Life Technologies,
Bleiswijk, The Netherlands), and 1 µL of primers and probe mixture for detection of RSV A, RSV B,
and PDV in a triplex reaction (Table S1). The RT-PCR temperature profile was 5 min at 50 ◦C, 20 sec
at 95 ◦C, 45 cycles of 3 s at 95 ◦C, and 32 s at 60 ◦C.
Dilutions of an electron microscopic-counted HRSV stock (ABIOnline.com Columbia) were used
for conversion of RT-PCR threshold cycle (Ct) values into a quantitative measurement of viral particles.
Concentrations of viral RNA are expressed as log10 vp/mL. Infectious virus titers in tissue are
expressed as log10 TCID50 per gram tissue, and infectious virus titer in throat and nose swabs are
expressed as log10 TCID50/mL. Significant differences in shedding loads were assessed based on the
areas under the curve and using the Student t-test.
Formalin-fixed tissue sections of nasal turbinates, trachea, and left lung were routinely processed,
paraffin embedded, and sectioned at 3–4 µm, deparaffinized with xylene and rehydrated using graded
alcohols, and stained with hematoxylin and eosin (H&E) for histopathological examination by light
microscopy. For immunohistochemistry (IHC), additional serial slides were sectioned simultaneously
and incubated for 1 h with a goat anti-HRSV-peroxidase (PO) (Virostat, Portland, ME, USA)
polyclonal antibody following antigen retrieval using citric acid buffer. Endogenous PO was
blocked with 3% hydrogen peroxide. The bound PO was visualized by incubating slides with
3-amino-9-ethylcarbazole for 10 min as substrate, resulting in a reddish brown finely-granular staining
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of HRSV-infected epithelial cells, followed by hematoxylin counterstain. Negative controls were
performed in the absence of the antibody.
2.5. Nested PCR Amplification and Sanger Sequencing
Full-length F and G gene sequencing was performed on the inoculum virus and RT-PCR
positive nose and/or throat swabs collected from the donor ferrets at 5 and 11 dpi and from
the contact ferrets at 6 dpe (corresponding to 11 dpi). RNA extraction was performed using a
MagNA Pure 96 (Roche Diagnostics) and MagNA Pure 96 DNA and Viral NA Small Volume Kit
with an input volume of 200 µL and output volume of 100 µL according to the manufacturer’s
instructions (Roche Applied Science). cDNA synthesis was performed using Superscript III Reverse
Transcriptase (Invitrogen, Carlsbad, CA, USA). Semi-nested PCR amplification was performed using
HotStarTaq DNA Polymerase (Qiagen, Hilden, Germany). Sequence reactions were performed with
the BigDye®Terminator v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) and an
ABI Prism 3730 genetic analyzer. Primers are indicated in Table S1.
3. Results
3.1. Donor Ferrets
All donor ferrets inoculated with HRSV either intra-tracheally (group A) or intra-nasally (group B)
developed a productive infection. Both HRSV RNA and replication-competent virus were detected in
throat and nose swabs of group A and group B ferrets (Figure 2).
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Figure 2. HRSV RNA concentrations and viral titers in the throat and nose swabs of donor ferrets;
(a) HRSV concentration in the throat swabs (plain line) and nose swabs (dashed line) of group A ferrets
inoculated intra-tracheally (I.T); (b) HRSV viral titers in the throat swabs (plain line) and nose swabs
(dashed line) of group A ferrets inoculated intra-tracheally (I.T); (c) HRSV concentration in the throat
swabs (plain line) and nose swabs (dashed line) of group B ferrets inoculated intra-nasally (I.N);
(d) HRSV viral titers in the throat swabs (plai line) and nose sw bs (d shed li e) of group B
ferrets inoculated intra-nasally (I.N); each line represents a single ferret; for (a,c): quantification limit
of qPCR data is indicated by a dotted line, and non-quantifiable Ct values were assigned the
value 1.3 log10 vp/mL.
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Detectable RNA concentrations and viral titers in throat and nose swabs were typically recorded
from 3–4 dpi to 10–13 dpi, except in the nose swabs of group A ferrets, with quantifiable RNA
concentrations and viral titers appearing later, between 6 and 10 dpi. In group A ferrets, viral RNA
concentrations and viral titers were found to be significantly higher in the throat swabs than in the nose
swabs, based on the areas under the curve (3.17x, p = 0.04 and 3.21x, p = 0.04, respectively; Figure 3).
Viral RNA concentrations and viral titers in the nose swabs of group A ferrets were significantly lower
than in the nose swabs of group B ferrets, based on the areas under the curve (−4.05x, p = 0.03 and 4.8x,
p = 0.02, respectively; Figure 3). HRSV RNA concentrations and viral titers in organ samples and BAL
are given in Table 1.
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Table 1. HRSV viral titers (log10 TCID50/g) and RNA concentrations (log10 virus particles (vp)/mL)
in sampled tissues of the respiratory tract of donor and contact ferrets.
Ferret Viral Titers (log10 TCID50/g) RT-PCR (log10 vp/mL)
Group Number Nasal Turbinates Trachea Primary Bronchus Lung BAL Lung BAL
A.
1 4.9 2.1 - 2.9 5 8.8 7.3
2 - - - - - 6.9 5.2
B.
3 6.1 1.7 2.3 4.2 6.8 7.5 7.1
4 - - - - - 5.8 3.2
C.
5 5.3 1.4 - - 2.8 5.6 2.9
6 - 3.3 - - 4.3 6.5 5.8
7 4.3 3 - 2.9 4.5 6 5.5
8 - - - - - - -
9 6.1 1.7 - - - NQ NQ
D.
15 - 1.5 - 2.3 - 6.4 4.3
16 5 - - - 1.8 5.3 4.3
17 - - - - - - -
18 - - - - - NQ 3.9
19 3.4 - - - - - -
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Table 1. Cont.
Ferret Viral Titers (log10 TCID50/g) RT-PCR (log10 vp/mL)
Group Number Nasal Turbinates Trachea Primary Bronchus Lung BAL Lung BAL
E.
10 6.7 3.5 - 2.4 - 6.5 4.4
11 6.5 5.2 - 3.2 3.5 6.6 5.5
12 6.2 5.3 - 3.1 5.8 6.5 6.4
13 4.6 2.3 - - 1.8 5.6 NQ
14 - - - - - 5.7 NQ
F.
20 - - - - - NQ -
21 1.4 - - - - - -
22 3.7 - - - - NQ -
23 - - - - - NQ NQ
24 - - - 2.2 - 5.3 NQ
NQ: non quantifiable Ct values.
Upon microscopic examination, pathological changes were observed in some of the respiratory
tissues sampled from group A and group B ferrets (Figure 4). In each group, cells positive for
HRSV-antigen were detected by immunohistochemistry in one of the inoculated ferrets. In the group A
positive ferret, positive cells were found in small to moderate number in ciliated epithelial cells of the
nasal turbinates, trachea, primary bronchus, and bronchioles. Positive syncytial cells were observed in
the nasal turbinates. In the group B positive ferret, positive cells were found in moderate number in
ciliated epithelial cells of the primary bronchus and in large number in ciliated epithelial cells of the
nasal turbinates and trachea, including positive syncytial cells (Figure 4).
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Figure 4. Photomicrographs of intranasally HRSV-inoculated immunocompromised donor ferret
(animal #3) inflamed mucosa of the nasal turbinates at 13 dpi (a,b) and of immunocompromised
contact ferr t (animal #10) tracheal mucosa following productive HRSV transmission at 8 days
post-exposure (c,d). (a) RSV-infected epithelial cells may develop bright eosinophilic viral inclusion
bodies (arrows) and may form syncytial multinucleated cells (H&E-stain); (b) Serial slide shows
HRSV-antigen expression faintly of the cytoplasmic inclusion bodies (arrows) enclosed by a corona
of multiple nuclei, and markedly of the outer cellular membranes and cilia of RSV-infected nasal
epithelial c lls as red-brown staining (Immunoperoxidase, hematoxylin-counterstain); (c) The mucosa
is markedly inflamed with infiltrated neutrophils and covered with layer of exud te (asterisk);
multinucleated epithelial syncytial cells containing bright eosinophilic viral inclusion bodies
(arrows) are present within RSV-infected tracheal epithelial cells (H&E-stain); (d) Serial slide
shows HRSV-antigen expression faintly of the cytoplasmic inclusion bodies (arrows) and markedly
of the apical side and cilia of RSV-infected tracheal epithelial cells as red-brown staining
(Immunoperoxidase, hematoxylin-counterstain). Original magnifications 400×.
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3.2. Contact Ferrets
HRSV was detected by RT-PCR in the throat swabs of four to five contact ferrets, and in
the nose swabs of two to four contact ferrets in each of the four groups C–F (Table 2).
HRSV replication-competent virus was detected in the throat swabs of three to four contact ferrets,
and in the nose swabs of one to three contact ferrets in each of these four groups (Table 2). HRSV was
detected from day 4–6 to day 8 post-exposure (dpe) in the positive contact ferrets. HRSV RNA
concentrations and viral titers were similar in these four groups based on the areas under the curve.
In general, viral titers were higher in the throat swabs than in the nose swabs of the contact ferrets
(Figure S1). They tended to reach similar peak values in the throat swabs, yet lower peak values in the
nose swabs than those in the donor ferrets (Figure S1). HRSV RNA and replication-competent virus
was detected in the lung and or BAL of at least one contact ferret in each of the four groups of contact
ferrets. RNA concentrations and viral titers in organ samples and BAL of the contact ferrets are given
in Table 1.
Table 2. Number of ferrets with throat and nose swabs positive for HRSV RNA and for
replication-competent HRSV.
Ferret Group Throat Swab RT-PCR Nose Swab RT-PCR Throat Swab VI Nose Swab VI
A (N = 2) 2 2 2 2
B (N = 2) 2 2 2 2
C (N = 5) 4 3 4 2
D (N = 5) 4 4 4 3
E (N = 5) 4 2 4 2
F (N = 5) 5 4 3 1
Upon microscopic examination, pathological changes were observed in several of the respiratory
tissues sampled from contact ferrets. The infected mucosae of, especially, the tracheas and nasal
turbinates showed mild inflammation characterized by infiltration of mainly neutrophils within
the epithelial lining accompanied by exfoliation of degenerated and/or infected epithelial cells and
intraluminal exudation of fibrinous material. Large, bright eosinophilic inclusion bodies composed of
viral protein may be present within the cytoplasm of infected epithelial cells (Figure 4). In each group,
cells positive for HRSV-antigen were detected by immunohistochemistry in one to three contact ferrets.
In group C, positive ciliated epithelial cells were found in the trachea and primary bronchus of one
contact ferret. In group D, positive ciliated epithelial cells were found in the nasal turbinates or trachea
of three contact ferrets. In group E, positive ciliated epithelial cells were found in the trachea and/or
primary bronchus of three contact ferrets, including positive syncytial cells (Figure 4). In group F,
positive ciliated epithelial cells were found in the nasal turbinates of one contact ferret.
3.3. Virus
A low-passage clinical isolate of HRSV was used to inoculate the donor ferrets. The F and G
genes of the inoculum virus, as well as of shed virus sampled from the throat or nose swabs of donor
and contact ferrets, were sequenced to evaluate any genetic changes potentially marking adaptation
to the ferret model (Table S2). Three substitutions in the HRSV G protein and one substitution in
HRSV F protein were detected in four of the contact ferrets. Point mutations resulted in amino acid
changes T226I in the G protein in animal #5 (group C), Q81Q/L in the G protein in animal #7 (group C),
N20N/D in the G protein in animal #14 (group D), and T244T/A in the F protein in animal #23
(group F). No consistent changes in amino acid sequences were observed, suggesting that transmission
of virus is independent of virus adaptation to ferrets.
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4. Discussion
Immunocompromised ferrets inoculated with HRSV can transmit the virus to contact ferrets that
are either immunocompromised or immunocompetent. In general, HRSV viral loads were found similar
in immunocompromised and immunocompetent contact ferrets. Although immunocompromised
ferrets inoculated intra-nasally tended to have higher RNA or viral loads in the nose swabs than
immunocompromised ferrets inoculated intra-tracheally, HRSV was transmitted as efficiently from
either group to contact ferrets.
The transmission rate of HRSV in our ferret model using a low-passage HRSV isolate is
high, reaching 80 to 100%, based on RT-PCR results. In contrast to the study by Chan et al. [18],
we chose to use the immunocompromised ferret model as donors for transmission studies, as it
is more relevant for the clinical situation, and in addition more and longer HRSV shedding was
observed [16]. It demonstrates the potential of these models to be used for the quantitative assessment
of HRSV transmission in the context of intervention studies. The immunocompromised donor ferrets
reproduced a prolonged infection with high RNA and viral loads in nose and throat swabs as described
previously, confirming the robustness of the model [16]. Ferrets inoculated intra-nasally developed
higher RNA and viral loads in the nose than ferrets inoculated intra-tracheally. Ferrets inoculated
intra-nasally also tended to have more cells positive for HRSV-antigen in the upper regions of the
respiratory tract, i.e., in the nasal turbinates and trachea than ferrets inoculated intra-tracheally.
Conversely, ferrets inoculated intra-tracheally tended to have more positive cells for HRSV-antigen
deeper down the respiratory tract, in the bronchi and bronchioles, than ferrets inoculated intra-nasally.
This supports the fact that the route of transmission can have an impact on HRSV kinetics upon
infection, as previously shown for influenza A virus in ferrets [21,22].
Both immunocompromised and immunocompetent contact ferrets effectively developed
a productive infection following contact transmission of HRSV. In both donor and contact
immunocompromised and immunocompetent ferrets, ciliated epithelial cells along the respiratory
tract, from the nasal turbinates to the bronchi and bronchioles, were found infected, in association
with inflammatory lesions. Only a few substitutions were sporadically detected in the F and G
proteins of HRSV shed by contact ferrets, suggesting that little adaptation to the ferret model had
occurred during the prolonged infection in donor immunocompromised ferrets and upon contact
transmission. These observations further support the appropriateness of the ferret model to reproduce
HRSV infection and pathogenesis as seen in humans, including after contact transmission of the
virus. The use of a contact transmission model nonetheless precludes the assessment of the respective
role of large droplets and aerosols in the transmission of HRSV. However, and despite differences in
RNA and viral loads in the nose, donor ferrets inoculated intra-nasally and donor ferrets inoculated
intra-tracheally transmitted HRSV to contact ferrets with similar efficiency. This suggests that HRSV
transmission in these ferret models does not correlate with viral loads in the upper respiratory tract.
Future studies using molecularly cloned HRSV constructs expressing a reporter gene, like EGFP,
may facilitate studies of transmission mechanisms of HRSV.
In conclusion, the ferret models presented in this paper can be used to mimic nosocomial
transmission of HRSV in vulnerable patients, as well as population-based transmission in humans,
and also can be used to evaluate intervention strategies for the prevention of HRSV transmission.
Supplementary Materials: The following are available online at www.mdpi.com/1999-4915/10/1/18/s1,
Figure S1: HRSV virus titer in throat and nose swabs of donor and contact ferrets; Group A: donor ferrets
inoculated intra-tracheally; Group B: donor ferrets inoculated intra-nasally; Group C: immunocompromised
ferrets in contact with group A ferrets; Group D: immunocompetent ferrets in contact with group A ferrets;
Group E: immunocompromised ferrets in contact with group B ferrets; Group F: immunocompetent ferrets in
contact with group B ferrets; each line represents a single ferret; Table S1: RT-PCR and sequencing primers and
probes; Table S2: Sequence mutations in the F and G genes of virus shed from donor and contact ferrets compared
to the inoculum virus.
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